Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15749898 | 0.95 | ALDH1A1 (0.41) | ALDH1A1 | |
| SCHEMBL12228692 | 0.91 | ALDH1A1 (0.40) | ALDH1A1 | |
| SCHEMBL7031523 | 0.83 | CYP1A2 (0.40) | ALDH1A1 | |
| SCHEMBL17645782 | 0.71 | CYP1A2 (0.31) | ALDH1A1 | |
| SCHEMBL3046027 | 0.71 | CYP1A2 (0.31) | ALDH1A1 | |
| SCHEMBL3046028 | 0.71 | ALDH1A1 (0.37) | ALDH1A1 | |
| SCHEMBL9320849 | 0.71 | PTGS1 (0.36) | ALDH1A1 | |
| SCHEMBL5783976 | 0.71 | CA2 (0.33) | ALDH1A1 | |
| SCHEMBL14730379 | 0.71 | ALDH1A1 (0.31) | ALDH1A1 | |
| SCHEMBL23934777 | 0.71 | CA1 (0.41) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8093206-B2 | Methods involving long lasting synthetic exendin-4 peptide conjugates | CONJUCHEM, LLC (US) | 2012-01-10 | — | — | US | disclosed |
| US-8026265-B2 | Heterocycle substituted ketone derivatives as histone deacetylase (HDAC) inhibitors | Istituto de Ricerche di Biologia Molecolare P. Angeletti SpA. (IT) | 2011-09-27 | — | — | US | disclosed |
| US-20100234374-A1 | Heterocycle Substituted Ketone Derivatives as Histone Deacetylase (HDAC) Inhibitors | MSD ITALIA S.R.L. (IT) | 2010-09-16 | — | — | US | disclosed |
| US-7745413-B2 | Collection of traceable compounds and uses thereof | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 2010-06-29 | — | — | US | disclosed |
| US-7625938-B2 | Substituted pyrazoles, compositions containing such compounds and methods of use | MERCK & CO., INC. (US) | 2009-12-01 | — | — | US | disclosed |
| US-20090175821-A1 | Modified therapeutic peptides with extended half-lives in vivo | CONJUCHEM, LLC | 2009-07-09 | — | — | US | disclosed |
| US-20090093408-A1 | Protection of exendin-4 peptides through conjugation | CONJUCHEM, LLC | 2009-04-09 | — | — | US | disclosed |
| US-20090075890-A1 | Long lasting synthetic exendin-4 peptide conjugates and methods of use thereof | CONJUCHEM BIOTECHNOLOGIES INC. | 2009-03-19 | — | — | US | disclosed |
| US-7482372-B2 | Hydantoins and related heterocycles as inhibitors of matrix metalloproteinases and/or TNF-α converting enzyme (TACE) | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-01-27 | — | — | US | disclosed |
| US-7456184-B2 | Melanocortin receptor-specific compounds | PALATIN TECHNOLOGIES INC. (US) | 2008-11-25 | — | — | US | disclosed |
| US-20080176763-A1 | Collection of Traceable Compounds and Uses Thereof | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2008-07-24 | — | — | US | disclosed |
| US-7256253-B2 | Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components | CONJUCHEM BIOTECHNOLOGIES INC. (CA) | 2007-08-14 | — | — | US | disclosed |
| US-20070082940-A1 | Novel 1-aryl-3-azabicyclo[3.1.0]hexanes: preparation and use to treat neuropsychiatric disorders | OTSUKA AMERICA PHARMACEUTICAL, INC. | 2007-04-12 | — | — | US | disclosed |
| US-20030055297-A1 | An alkyl, cycloalkyl, arylalkyl dihydroxy compound useful as intermediates; a cost-effective preparation | ABBOTT LABORATORIES | 2003-03-20 | — | — | US | disclosed |
| WO-2002081441-A1 | PROCESS FOR THE PREPARATION OF SUBSTITUTED PYRROLIDINE NEURAMINIDASE INHIBITORS | ABBOTT LABORATORIES (US) | 2002-10-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070082940-A1 | Novel 1-aryl-3-azabicyclo[3.1.0]hexanes: preparation and use to treat neuropsychiatric disorders | HTR3C, HTR1B, HTR2C | ALDH1A1 176/4885 |
| US-20090175821-A1 | Modified therapeutic peptides with extended half-lives in vivo | DNPEP, ANPEP, ENPEP | ALDH1A1 3322/4885 |
| US-20090075890-A1 | Long lasting synthetic exendin-4 peptide conjugates and methods of use thereof | IAPP, VIP, GLP1R | ALDH1A1 4121/4885 |
| US-20030055297-A1 | An alkyl, cycloalkyl, arylalkyl dihydroxy compound useful as intermediates; a cost-effective preparation | NEU4, NEU2, NEU1 | ALDH1A1 410/4885 |
| US-20100234374-A1 | Heterocycle Substituted Ketone Derivatives as Histone Deacetylase (HDAC) Inhibitors | HDAC1, HDAC7, HDAC4 | ALDH1A1 950/4885 |
| US-20090093408-A1 | Protection of exendin-4 peptides through conjugation | VIP, PEPD, ANPEP | ALDH1A1 4179/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.